Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Byrd JC, et al. J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26. J Clin Oncol. 2021. PMID: 34310172 Free PMC article. Clinical Trial.
Chronic lymphocytic leukemia.
Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Kay NE, et al. Among authors: byrd jc. Hematology Am Soc Hematol Educ Program. 2002:193-213. doi: 10.1182/asheducation-2002.1.193. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446424 Review.
Zanubrutinib in Chronic Lymphocytic Leukemia.
Byrd JC, Rothbaum W. Byrd JC, et al. N Engl J Med. 2023 May 4;388(18):1719-1720. doi: 10.1056/NEJMc2302350. N Engl J Med. 2023. PMID: 37133595 No abstract available.
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Burd A, et al. Among authors: byrd jc. Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26. Nat Med. 2020. PMID: 33106665 Free PMC article. Clinical Trial.
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
Walker JS, Hing ZA, Sher S, Cronin J, Williams K, Harrington B, Skinner JN, Cempre CB, Gregory CT, Pan A, Yano M, Beaver LP, Walker BR, Labanowska JM, Heerema NA, Mrózek K, Woyach JA, Ruppert AS, Lehman A, Ozer HG, Coppola V, Yan P, Byrd JC, Blachly JS, Lapalombella R. Walker JS, et al. Among authors: byrd jc. Nat Commun. 2021 Nov 3;12(1):6338. doi: 10.1038/s41467-021-26400-x. Nat Commun. 2021. PMID: 34732719 Free PMC article.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Saliba AN, et al. Among authors: byrd jc. Blood Adv. 2023 Jun 13;7(11):2360-2363. doi: 10.1182/bloodadvances.2022008625. Blood Adv. 2023. PMID: 36315007 Free PMC article. Clinical Trial. No abstract available.
846 results